Abstract
Objective: To predict the risk of diabetic nephropathy in patients with type 2 Diabetes Mellitus using Mean platelet volume to lymphocyte ratio (MPVLR) and comparison with diabetics without nephropathy. Material and Methods: This Cross-sectional study was conducted at Chughtai Institute of Pathology, in Lahore, Pakistan from July to December 2021. 100 Patients with type 2 Diabetes mellitus were included. Two groups were made based on the urinary microalbumin/creatinine ratio: diabetic nephropathy and non-nephropathy group. MPVLR derived by dividing MPV to total lymphocyte count. Results: There were a total of 100 subjects. Mean age of patients of group A was 45.99±13.42 years while mean age of patients of group B was 41.87±14.65 years and p-value 0.105. 75.2% patients of group A were female while 82.1% patients of group B were female (p-value 0.185). The MPVLR of group A was 45.51±8.32 while of group B was 70.33±13.40 (p-value 0.001). The best cut-off value for MPVLR when compared with those of group B indicated a P value that is evident and in relation to that given in literature proving the hypothesis. Conclusion: The MPVLR is an easily calculated and efficient index and higher values indicate inflammation. It may be considered an independent and reliable predictor of diabetic nephropathy. We suggest, it can be a useful complement to standard tests in labeling diabetic nephropathy. Key Words: HBA1C, Diabetic nephropathy, Platelet indices, Mean platelet volume to lymphocyte ratio
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.